Want to see NYMXF full AI Analyst Report?
NYMXF Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.20
Previous CloseN/A
Volume3.00
Average Volume (3M)21.72K
Market Cap
$1.89M
Enterprise Value$10.33M
Total Cash (Recent Filing)$74.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-358.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding94,540,140
10 Day Avg. Volume24,882
30 Day Avg. Volume21,717
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.38
Price to Sales (P/S)0.00
P/FCF Ratio-3.60
Enterprise Value/Market Cap5.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focus On Unmet Medical NeedsTargeting unmet medical needs can lead to significant market opportunities if the company successfully develops effective treatments, particularly in aging-related conditions where demand is growing.
Lead Product CandidateA focused development on a lead product candidate can streamline resources and increase the likelihood of achieving regulatory approval, potentially unlocking revenue streams through commercialization.
Potential PartnershipsPotential partnerships and licensing agreements can provide crucial funding and resources, enhancing the company's ability to bring products to market and share risks with established players.
Bears Say
Persistent Financial LossesOngoing financial losses and negative equity indicate severe financial instability, which could hinder long-term operations and the ability to fund R&D activities necessary for future growth.
Negative Cash FlowNegative cash flow suggests the company is burning cash without generating sufficient operational income, which may necessitate further financing and dilute shareholder value.
Lack Of Revenue GrowthThe lack of revenue growth and high negative margins highlight severe profitability issues, questioning the company's ability to sustain operations and achieve financial stability.
Nymox Pharmaceutical News
NYMXF FAQ
What was Nymox Pharmaceutical’s price range in the past 12 months?
Nymox Pharmaceutical lowest stock price was $0.01 and its highest was $0.20 in the past 12 months.
What is Nymox Pharmaceutical’s market cap?
Nymox Pharmaceutical’s market cap is $1.89M.
When is Nymox Pharmaceutical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nymox Pharmaceutical’s earnings last quarter?
Currently, no data Available
Is Nymox Pharmaceutical overvalued?
According to Wall Street analysts Nymox Pharmaceutical’s price is currently Overvalued.
Does Nymox Pharmaceutical pay dividends?
Nymox Pharmaceutical does not currently pay dividends.
What is Nymox Pharmaceutical’s EPS estimate?
Nymox Pharmaceutical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nymox Pharmaceutical have?
Nymox Pharmaceutical has 94,540,140 shares outstanding.
What happened to Nymox Pharmaceutical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nymox Pharmaceutical?
Currently, no hedge funds are holding shares in NYMXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nymox Pharmaceutical
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.
Technical Analysis
Evogene
―
Mustang Bio
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors